Among these molecules, compound 6a showed the potential for competing with the puc_SBC1 peptide to bind to SPOP, while compound 6b was found to exert a strong inhibitory activity in disrupting the SPOP-PTEN and SPOP-DUSP7 interaction and blocking the downstream PTEN/Akt pathway in vitro, inhibiting the proliferation of A498 ccRCC cells [142]. The gene discussed is PTEN; the disease is nonpapillary renal cell carcinoma.